Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486664 | 0.89 | ALDH1A1 (0.41) | MAPTCCNT1CDK9TSHRHTT | |
| SCHEMBL12891138 | 0.87 | TSHR (0.41) | MAPTLMNACCNT1CDK9TSHR | |
| SCHEMBL13913115 | 0.87 | TSHR (0.41) | MAPTLMNACCNT1CDK9TSHR | |
| SCHEMBL25614635 | 0.81 | PTGS2 (0.50) | MAPTHPGDHTTCALM1 | |
| SCHEMBL9927129 | 0.81 | DAO (0.42) | MAPTCCNT1CDK9TSHRHTT | |
| SCHEMBL9055023 | 0.81 | TSHR (0.36) | MAPTCCNT1CDK9TSHRHTT | |
| SCHEMBL1346785 | 0.79 | PGK1 (0.47) | LMNAHPGD | |
| SCHEMBL16897969 | 0.78 | TP53 (0.32) | GAA | |
| SCHEMBL13913134 | 0.77 | TSHR (0.50) | MAPTCCNT1CDK9TSHRHTT | |
| SCHEMBL30323683 | 0.76 | CMA1 (0.47) | MAPTLMNACCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| CN-101939297-B | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO | 2012-10-17 | — | — | CN | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| CN-101939297-A | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO | 2011-01-05 | — | — | CN | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | MAPT 3712/4885LMNA 3893/4885HPGD 1917/4885 |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | MAPT 3712/4885LMNA 3893/4885HPGD 1917/4885 |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | MAPT 3712/4885LMNA 3893/4885HPGD 1917/4885 |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | MAPT 3712/4885LMNA 3893/4885HPGD 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.